anti-HER2 CAR T-cell therapy (Shanghai First Song Therapeutics)

N/A

Report date: 2025/06/11 20:01:15

Base Information

Drug Nameanti-HER2 CAR T-cell therapy (Shanghai First Song Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulatorsT lymphocytes stimulantsImmunostimulants
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursPancreatic Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Simcere Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Simcere Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursPancreatic Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A